ITGAV and prostate carcinoma: Further, it was found that treatment with CD51 antagonist could suppress de novo formation and progression of bone metastases in CRPC by inhibiting EMT process and decreasing the prostate cancer stem cell population (pCSC) population (van der Horst et al., 2011).